Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

被引：0
|
作者：
Nadal, R. [1 ]
Mortazavi, A. [2 ]
Stein, M. [3 ]
Pal, S. K. [4 ]
Davarpanah, N. [1 ]
Parnes, H. L. [1 ]
Ning, Y. M. [1 ]
Cordes, L. M. [1 ]
Lin, J. [1 ]
Bagheri, M. [5 ]
Linderberg, L. [1 ]
Berniger, M. [1 ]
Steinberg, S. M. [6 ]
Moore, T. [4 ]
Lancaster, T. [2 ]
Aviles, M. [3 ]
Costello, R. [1 ]
Bottaro, D. P. [1 ]
Dahut, W. L. [1 ]
Apolo, A. B. [1 ]
机构：
[1] NCI, Med Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Ohio State Univ, Internal Med, James Canc Hosp, Columbus, OH 43210 USA
[3] Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA
[4] City Hope Natl Med Ctr, Med Oncol, Duarte, CA USA
[5] NCI, Ctr Canc Res, Radiol & Imaging Sci, Bethesda, MD 20892 USA
[6] NCI, Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD 20892 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
    Nadal, Rosa Maria
    Mortazavi, Amir
    Stein, Mark
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Parnes, Howard L.
    Ning, Yang-Min
    Cordes, Lisa M.
    Bagheri, Mohammadhadi H.
    Lindenberg, Liza
    Thompson, Ryan
    Steinberg, Seth M.
    Moore, Tina
    Lancaster, Tiffany
    Velez, Milisyaris
    Mena, Esther
    Costello, Rene
    Bottaro, Donald
    Dahut, William L.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors
    Apolo, A. B.
    Mortazavi, A.
    Stein, M.
    Pal, S. K.
    Davarpanah, N.
    Parnes, H. L.
    Ning, Y. M.
    Francis, D. C.
    Cordes, L. M.
    Berniger, M.
    Steinberg, S. M.
    Monk, P.
    Lancaster, T.
    Mayer, T.
    Costello, R.
    Bottaro, D. P.
    Dahut, W. L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.
    Apolo, Andrea B.
    Mortazavi, Amir
    Stein, Mark N.
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Parnes, Howard L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [4] A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
    Apolo, Andrea B.
    Mortazavi, Amir
    Stein, Mark N.
    Davarpanah, Nicole N.
    Nadal, Rosa Maria
    Parnes, Howard L.
    Ning, Yangmin M.
    Francis, Deneise C.
    Cordes, Lisa M.
    Berniger, Marilise Anne
    Steinberg, Seth M.
    Agarwal, Piyush K.
    Bagheri, Mohammadhadi H.
    Nanda, Swati
    Monk, Paul
    Lancaster, Tiffany
    Moore, Tina
    Costello, Rene
    Bottaro, Donald P.
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib plus nivolumab (CaboNivo) or cabozantinib plus nivolumab plus ipilimumab (CaboNivoIpi).
    Niglio, Scot Anthony
    Girardi, Daniel Motta
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Combined FDG and NaF PET/CT study in patients (pts) with metastatic genitourinary tumors (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /-Ipi)
    Lin, Jeffrey
    Mortazavi, Amir
    Stein, Mark N.
    Pal, Sumanta K.
    Davarpanah, Nicole N.
    Nadal, Rosa Maria
    Francis, Deneise C.
    Berniger, Marilise Anne
    Monk, Paul
    Kempf, Jeffrey
    Becker, Murray
    Sokol, Levi
    McKinney, Yolanda
    Knopp, Michael V.
    Wright, Chadwick
    Jung, Alex
    Choyke, Peter L.
    Mena, Esther
    Lindenberg, Liza
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Nivolumab (NIVO) plus ipilimumab (IPI) plus cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040
    Yau, Thomas
    Zagonel, Vittorina
    Santoro, Armando
    Acosta-Rivera, Mirelis
    Choo, Su Pin
    Matilla, Ana
    He, Aiwu Ruth
    Gracian, Antonio Cubillo
    El-Khoueiry, Anthony B.
    Sangro, Bruno
    Eldawy, Tarek
    Bruix, Jordi
    Frassineti, Giovanni
    Vaccaro, Gina M.
    Tschaika, Marina
    Scheffold, Christian
    Shen, Yun
    Neely, Jaclyn
    Piscaglia, Fabio
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [8] The association of FDG PET/CT and NaF PET/CT with survival outcomes in patients (pts) with metastatic genitourinary malignancies (mGU) treated with cabozantinib plus nivolumab plus /- ipilimumab (CaboNivo plus /- Ipi).
    Simon, Nicholas I.
    Lei, Katherine
    Verdini, Nicholas Peter
    Lin, Jeffrey
    Vega, Andy
    Niglio, Scot Anthony
    Mortazavi, Amir
    Pal, Sumanta K.
    Kempf, Jeffrey
    Becker, Murray
    Knopp, Michael V.
    Wright, Chadwick
    Jung, Alex
    Choyke, Peter L.
    Steinberg, Seth M.
    Mena, Esther
    Lindenberg, Liza
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) plus /- ipilimumab (CaboNivolpi).
    Hu, Zishuo
    Mortazavi, Amir
    Pal, Sumanta K.
    Lara, Primo
    Mayer, Tina M.
    Steinberg, Seth M.
    Mayfield, Christian
    Graap, Katherine
    Mallek, Marissa
    Costello, Rene
    Diaz, Carlos
    Schonhoft, Joseph
    Wang, Yipeng
    Dittamore, Ryan
    Chu, Lincy
    Trepel, Jane B.
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) plus /- ipilimumab (CaboNivolpi).
    Apolo, Andrea B.
    Mortazavi, Amir
    Hu, Zishuo Ian
    Schonhoft, Joseph
    Chu, Lincy
    Anderson, Amanda K. L.
    Wang, Yipeng
    Dittamore, Ryan
    Pal, Sumanta K.
    Lara, Primo
    Stein, Mark N.
    Steinberg, Seth M.
    Mayfield, Christian
    Cordes, Lisa M.
    Mallek, Marissa
    Costello, Rene
    Diaz, Carlos
    Trepel, Jane B.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345